Devyser today announces that Sabina Berlin, current CFO, will transition to a new role with responsibility for Investor Relations and Corporate Compliance. At the same time, the company has appointed Niklas Axelsson as the new Chief Financial Officer (CFO).
Niklas Axelsson has more than 25 years of experience from the pharmaceutical, life science, and financial sectors. He spent nearly 20 years at AstraZeneca in senior finance roles, both in Sweden and internationally, and has experience from both commercial and strategic finance functions. Niklas is currently CFO of Diamyd Medical and has previously worked in corporate finance at Danske Bank.
“Devyser is in an exciting phase with continued international growth and an increased strategic focus. Niklas brings a strong combination of financial leadership, business acumen, and experience from complex international organizations,” says Jan Wahlström, CEO of Devyser.
Niklas Axelsson will assume the role in the second half of 2026, and no later than November 21, 2026. Sabina will continue as CFO until Niklas assumes the role.